CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Sanofi lifts expectations for 2026 sales growth, looks to M&A

By Reuters News

By Bhanvi Satija

LONDON, Oct 30 (Reuters) - French drugmaker Sanofi SASY.PA said on Friday it expects sales to grow by a "low-teens percentage" this year, up from a previous forecast of 10% sales growth, banking on strong demand for its blockbuster asthma drug Dupixent.

Sanofi also said that it now expects business operating income per share by a "mid-teens percentage". Previously, the company expected business operating income to grow slightly faster than sales.

New CEO Belen Garijo, who took over the top role at Sanofi in May and is leading a strategic review of the company, has promised investors faster decision-making. Several analysts believe M&A is needed to bring in new experimental drugs ahead of 2027, when most of its key late-stage data is expected.

CFO François Roger said on a call with journalists that the company is considering deals larger than the €2 billion to €5 billion range that it has historically done.

"We increase our interest for late-stage assets, phase three and potentially commercial assets," he said.

Roger added that the company is looking at areas of strength such as rare diseases, vaccines and immunology.

"We could consider potentially what we call white spaces or moonshots with unmet medical needs," he added.

Some analysts estimate that the company has about €20 billion in deal-making firepower.

The French drugmaker reported third-quarter business operating income of €5.43 billion, compared with market expectations of €4.32 billion, according to a company-provided analysts' consensus.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.